Usability of the MeTime MS App

NCT07123272 | Completed Results

• 2 other identifiers: HUM00268311K24AT012644
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

The Me Time MS Application was designed to enable self-administration of acupressure. Two forms of acupressure - either "relaxing" or "stimulating" protocols - are administered through the Me Time MS app. The goal of this study is to assess the usability of the Me Time MS app in a sample of 10 adults with multiple sclerosis (MS).

Conditions

Multiple Sclerosis; Pain; Fatigue Symptom

Keywords

chronic pain; acupressure; digital health; fatigue; usability; feasibility

Outcome Measures

Primary Outcomes (1)

• Participant Perception of Me Time MS App Usability

  Qualitative descriptions of positive, negative, and neutral aspects of usability of the Me Time MS app, gathered through one-on-one, open-ended interviews after 6 weeks of access to the app. Results reflect the total number of comments across all participants that were provided for each category. Participants could submit multiple types of comments.

  Up to 2 weeks after the 6-week app usage period ended

Secondary Outcomes (1)

• System Usability Scale (SUS) Adapted for the MeTime MS App

  Up to 2 weeks after the 6-week app usage period ended

Study Arms (2)

Relaxing Self-Acupressure

EXPERIMENTAL

Self-guided use of a smartphone app that informs users how to administer relaxing acupressure each day for 6 weeks.

Behavioral: Self-guided smartphone application for relaxing acupressure

Stimulating Self-Acupressure

EXPERIMENTAL

Self-guided use of a smartphone app that informs users how to administer relaxing acupressure each day for 6 weeks.

Behavioral: Self-guided smartphone application for stimulating acupressure

Interventions

Self-guided smartphone application for relaxing acupressure BEHAVIORAL

Relaxing Acupressure entails applying pressure with either a finger, pencil, or similar object to acupressure points. For the relaxing protocol, there is a total of 9 acupoints (1 unilateral and 4 bilateral). Each point will be stimulated for 3 minutes, yielding a total treatment time of 27 minutes each day. The acupoints are: 1. Yin Tang (Unilaterally): Located on the forehead, between the eyebrows. 2. Anmian (Right and Left/bilaterally): Located on the posterior aspect of the neck, in a slight depression along the bone directly behind the ear. 3. Heart 7 (HT7) (Right and Left/bilaterally): Located on the palmer surface of the hands on the wrist crease; in line with the pinky. 4. Spleen 6 (SP6) (Right and Left/bilaterally): Located on the inside of the lower leg, approximately 4 fingers width above the bone of the ankle. 5. Liver 3 (LIV3) (Right and Left/bilaterally): This point is located on the foot, near the big and second toes.

Also known as: Me Time MS

Relaxing Self-Acupressure

Self-guided smartphone application for stimulating acupressure BEHAVIORAL

There is a total of 10 acupoints (2 unilateral and 4 bilateral). Each point is stimulated for 3 minutes, yielding a total treatment time of 30 minutes each day. The acupoints are: 1. Du 20 (Unilaterally): Located at the top of the head. 2. Large Intestine 4 (LI4) (Right and Left/bilaterally): Located on the back of the hand, between your thumb and index finger. 3. Conception Vessel 6 (CV6) (Unilaterally): Located two finger widths below the navel on the centerline. 4. Stomach 36 (ST36) (Right and Left/bilaterally): Located on the lower leg below the knee on the outside of the leg. 5. Spleen 6 (SP6) (Right and Left/bilaterally): Located on the inside of the lower leg, approximately 4 fingers width above the bone of the ankle. 6. Kidney 3 (K3) (Right and Left/bilaterally): Located on the inside of the ankle.

Also known as: Me Time MS

Stimulating Self-Acupressure

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• MS diagnosis (all MS subtypes included)
• Age 18 years or older
• Average Fatigue Severity Scale (FSS) score ≥ 4 at screening coupled with the opinion of the volunteer that the fatigue has interfered with their daily activities for ≥ 3 months
• Presence of chronic pain defined as moderate to severe pain for ≥ 3-month duration that is ≥ 4 on average using a 0-10 numerical rating scale
• Home access to internet via Wi-Fi or cellular data
• Active email account

You may not qualify if:

• Not fluent in English
• Pregnancy or breast feeding, or anticipate pregnancy in next 6 months
• Inability to use smartphone/tablet and/or MeTime MS mobile app
• Anything at the discretion of the PI or study team that would preclude participation in the study

Sponsors & Collaborators

• University of Michigan: lead
• National Center for Complementary and Integrative Health (NCCIH): collaborator

Study Sites (1)

University of Michigan

Ann Arbor, Michigan, 48109, United States

Location

MeSH Terms

Conditions

Multiple Sclerosis; Pain; Fatigue; Chronic Pain

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: Anna Kratz
• Organization: University of Michigan

alkratz@med.umich.edu

734-647-5982

Study Officials

• Anna Kratz, PhD

  University of Michigan

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investogator

Study Record Dates

• First Submitted: August 7, 2025
• First Posted: August 14, 2025
• Study Start: March 17, 2025
• Primary Completion: May 16, 2025
• Study Completion: May 16, 2025
• Last Updated: November 20, 2025
• Results First Posted: November 20, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)